# Accurate International

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/accurate-international

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Website: www.bio-accurate.com/
- Total disclosed funding: $29M
- Latest round: Series B (May 19, 2025)
- Investors on record: 3

## About

Founded in 2018 and based in Guangzhou, China, Accurate International Biotechnology (Guangzhou) Co., Ltd develops and applies organoid technologies for use in cancer precision therapy, new drug development and regenerative medicine. The company operates across research, diagnosis and clinical application. 

Established in 2018 and based in Guangzhou, China, Accurate International has expanded its operations through three subsidiaries in Beijing, Shanghai and Macau. In 2022, the company launched its integrated platform for organoid-based R&D, diagnosis and personalized drug screening. In May 2025, the company raised approximately CNY 100 million in series B funding co-led by new investors Guangdong Technology Venture Capital and Toposcend Capital to accelerate the R&D, transformation and global commercial layout of organoid technology.

The company's self-developed products include Peixinan, an organoid-targeted drug sensitivity assay, Peixinkang, an individualized tumor companion diagnostic combining organoid drug sensitivity technology with second-generation sequencing technology, and Accuroid™, an organ culture and organoid drug sensitivity screening product. Their products are used in the field of scientific research, drug development, clinical application and precision tumor therapy.

The company generates revenue mainly through the sales of drugs and preclinical research services, clinical drug testing and collaborations with pharmaceutical and healthcare institutions.

The company aims to expand its automation capabilities and accelerate the R&D of personalized medicine and oncology drug following the latest round of funding.

## Funding rounds

- Series B, May 19, 2025, $14M — Toposcend Capital, Guangdong Technology Venture Capital
- Series A, Mar 12, 2021, $15M — Funway Capital

## Investors

- Funway Capital (https://capitalatlas.ai/funds/funway-capital) — Series A
- Toposcend Capital (https://capitalatlas.ai/funds/toposcend-capital) — Series B
- Guangdong Technology Venture Capital (https://capitalatlas.ai/funds/guangdong-technology-venture-capital) — Series B